骨桥蛋白配体及其与心血管疾病关系研究进展
Research Progress on Osteopontin Ligands and Their Relationship with Cardiovascular Diseases
DOI: 10.12677/acrvm.2025.131001, PDF,    科研立项经费支持
作者: 陆荣臻：右江民族医学院附属医院麻醉科，广西 百色；李近都*：广西医科大学附属肿瘤医院肝胆胰脾外科，广西 南宁；李天资：广西根辽生物技术有限公司科研科，广西 百色；陆 婷：右江区城中社区卫生服务中心，广西 百色
关键词: 骨桥蛋白；精氨酸–甘氨酸–天冬氨酸序列；肝素结合域；心血管疾病；Osteopontin； Arginine-Glycine-Aspartic Acid Sequence； Heparin Binding Domain； Cardiovasculars Diseases
摘要: 骨桥蛋白(OPN)是由骨桥蛋白基因(SPP1)编码的主要参与多种细胞功能的配体蛋白，是一种带负电的，非胶原性骨基质糖蛋白的，多数在细胞外基质(ECM)中发挥作用的一类重要的配体蛋白分子。OPN由胎盘等多种组织表达，含有信号肽、精氨酸–甘氨酸–天冬氨酸(Arg-Gly-Asp, RGD)、糖基化位点和肝素结合域等多种功能序列的转化相关性磷酸蛋白。多项研究证明OPN具有细胞粘附、细胞募集、细胞因子表达、信号转导、肿瘤发生和转移、细胞免疫、加速血管生成和纤维化等多种生物学功能，成为研究的热点，有意义的分子靶点不断被识别，逐渐成为疾病诊断和治疗的新靶标，本文对近年来OPN与心血管疾病的关系作简要综述。
Abstract: Osteopontin (OPN) is a negatively charged, non-collagenous bone matrix glycoprotein mainly in various cellular functions as a ligand protein. It is expressed in various tissues including placenta, and contains a signal peptide, arginine-glycinepartic acid (Arg-Gly-Asp, RGD), glycosylation sites, and heparin binding domains, among other functional sequences, as transforming-related acidic phosphoprotein. Numerous studies have shown that OPN has various biological functions such as cell adhesion, cell recruitment, cytokine expression, signalduction, tumorigenesis and metastasis, cellular immunity, angiogenesis, and fibrosis, making it a hot topic in research. Meaningful molecular targets continuously being identified, gradually becoming new targets for disease diagnosis and treatment. This article briefly reviews the relationship between OPN and cardiovascular diseases in recent years.
文章引用：陆荣臻, 李近都, 李天资, 陆婷. 骨桥蛋白配体及其与心血管疾病关系研究进展[J]. 亚洲心脑血管病例研究, 2025, 13(1): 1-10. https://doi.org/10.12677/acrvm.2025.131001

参考文献

[1] Song, Z., Chen, W., Athavale, D., Ge, X., Desert, R., Das, S., et al. (2021) Osteopontin Takes Center Stage in Chronic Liver Disease. Hepatology, 73, 1594-1608. [Google Scholar] [CrossRef] [PubMed]
[2] Shirakawa, K. and Sano, M. (2021) Osteopontin in Cardiovascular Diseases. Biomolecules, 11, Article 1047. [Google Scholar] [CrossRef] [PubMed]
[3] Icer, M.A. and Gezmen-Karadag, M. (2018) The Multiple Functions and Mechanisms of Osteopontin. Clinical Biochemistry, 59, 17-24. [Google Scholar] [CrossRef] [PubMed]
[4] Yim, A., Smith, C. and Brown, A.M. (2022) Osteopontin/Secreted Phosphoprotein‐1 Harnesses Glial‐, Immune‐, and Neuronal Cell Ligand‐Receptor Interactions to Sense and Regulate Acute and Chronic Neuroinflammation. Immunological Reviews, 311, 224-233. [Google Scholar] [CrossRef] [PubMed]
[5] Hao, C., Cui, Y., Owen, S., Li, W., Cheng, S. and Jiang, W.G. (2017) Human Osteopontin: Potential Clinical Applications in Cancer (Review). International Journal of Molecular Medicine, 39, 1327-1337. [Google Scholar] [CrossRef] [PubMed]
[6] Agah, E., Zardoui, A., Saghazadeh, A., Ahmadi, M., Tafakhori, A. and Rezaei, N. (2018) Osteopontin (OPN) as a CSF and Blood Biomarker for Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLOS ONE, 13, e0190252. [Google Scholar] [CrossRef] [PubMed]
[7] Scatena, M., Liaw, L. and Giachelli, C.M. (2007) Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 2302-2309. [Google Scholar] [CrossRef] [PubMed]
[8] Lu, H., Ng, D.Y.W., Lieberwirth, I., Weidner, T. and Bonn, M. (2021) Intrinsically Disordered Osteopontin Fragment Orders during Interfacial Calcium Oxalate Mineralization. Angewandte Chemie International Edition, 60, 18577-18581. [Google Scholar] [CrossRef] [PubMed]
[9] Orsi, G., Hayden, Z., Cseh, T., Berki, T. and Illes, Z. (2021) Osteopontin Levels Are Associated with Late-Time Lower Regional Brain Volumes in Multiple Sclerosis. Scientific Reports, 11, Article No. 23604. [Google Scholar] [CrossRef] [PubMed]
[10] Silva, G.R., Mattos, D.S., Bastos, A.C.F., Viana, B.P.P.B., Brum, M.C.M., Ferreira, L.B., et al. (2020) Osteopontin-4 and Osteopontin-5 Splice Variants Are Expressed in Several Tumor Cell Lines. Molecular Biology Reports, 47, 8339-8345. [Google Scholar] [CrossRef] [PubMed]
[11] Holzinger, J., Kotisch, H., Richter, K.W. and Konrat, R. (2021) Binding Mode Characterization of Osteopontin on Hydroxyapatite by Solution NMR Spectroscopy. ChemBioChem, 22, 2300-2305. [Google Scholar] [CrossRef] [PubMed]
[12] Hinterseher, I., Tromp, G. and Kuivaniemi, H. (2011) Genes and Abdominal Aortic Aneurysm. Annals of Vascular Surgery, 25, 388-412. [Google Scholar] [CrossRef] [PubMed]
[13] Arjomandi, M., Galanter, J.M., Choudhry, S., Eng, C., Hu, D., Beckman, K., et al. (2011) Polymorphism in Osteopontin Gene (spp1) Is Associated with Asthma and Related Phenotypes in a Puerto Rican Population. Pediatric Allergy, Immunology, and Pulmonology, 24, 207-214. [Google Scholar] [CrossRef] [PubMed]
[14] Comi, C., Cappellano, G., Chiocchetti, A., Orilieri, E., Buttini, S., Ghezzi, L., et al. (2012) The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression. Clinical and Developmental Immunology, 2012, 1-6. [Google Scholar] [CrossRef] [PubMed]
[15] Maver, A., Medica, I., Salobir, B., Tercelj, M. and Peterlin, B. (2009) Genetic Variation in Osteopontin Gene Is Associated with Susceptibility to Sarcoidosis in Slovenian Population. Disease Markers, 27, 295-302. [Google Scholar] [CrossRef] [PubMed]
[16] Lu, X., Zhang, J., Zhang, S., Qiao, J., Qiu, M., Liu, X., et al. (2021) Identification of Novel Hub Genes Associated with Gastric Cancer Using Integrated Bioinformatics Analysis. BMC Cancer, 21, Article No. 697. [Google Scholar] [CrossRef] [PubMed]
[17] Guo, Z., Huang, J., Wang, Y., Liu, X., Li, W., Yao, J., et al. (2020) Analysis of Expression and Its Clinical Significance of the Secreted Phosphoprotein 1 in Lung Adenocarcinoma. Frontiers in Genetics, 11, Article 547. [Google Scholar] [CrossRef] [PubMed]
[18] 周柳芳, 潘兴寿, 莫健姣, 等. 201例老年慢性心力衰竭患者6MWT步行试验反应的临床资料分析[J]. 亚洲心脑血管病例研究, 2023, 11(3): 17-24.
[19] 李丽玲, 彭宁福, 李近都, 等. 驱动蛋白14基因及其与子宫颈癌研究进展[J]. 临床医学进展, 2020, 10(3): 301-305.
[20] 赖腾芳, 李近都, 梁烨, 等. 慢性血管疾病患者抗血小板药物治疗反应及其与CYP2C19、APOE基因突变研究进展[J]. 中国医药科学, 2024, 14(13): 24-28.
[21] 韦宝敏, 潘兴寿, 李近都, 等. 整合素β3基因多态性蛋白质变异及其与疾病关系研究进展[J]. 中国医药科学, 2024, 14(1): 42-46.
[22] 潘兴寿, 李近都, 梁烨, 等. 野芭蕉对经皮冠状动脉介入术CYP2C19基因中间代谢表型患者的疗效观察[J]. 临床医学进展, 2023, 13(9):14935-14943.
[23] 赖腾芳, 李近都, 梁烨, 等. CYP2C19、APOE基因在慢性血管疾病中的表征及其与抗血小板药物研究进展[J]. 亚洲心脑血管病例研究, 2023, 11(1): 1-8.
[24] 李近都, 李天资, 黄照权, 等. 肝癌标本体外置留时间与核糖核酸测序质量的关系[J]. 中华实验外科杂志, 2018, 35(10): 1841.
[25] 黄达, 潘兴寿, 邹才华, 等. 冠心病患者血清TLR4水平增高及其与TLR4基因突变和临床的关系的研究[J]. 亚洲心脑血管病例研究, 2023, 11(2): 9-16.

为你推荐